Comparative proteome analysis of acute myeloid leukemia with and without maturation

Journal of Proteomics

Volumn 75, Issue 18, 2012, Pages 5734-5748

  Luczak, Magdalena ^a   Kaźmierczak, Maciej ^b   Handschuh, Luiza ^a,b   Lewandowski, Krzysztof ^b   Komarnicki, Mieczysław ^b   Figlerowicz, Marek ^a,c  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

2DE; Acute myeloid leukemia; Mass spectrometry; Proteome profiling

Indexed keywords

ACTIN; ACTIN GAMMA 1; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; LIPOCORTIN 1; PHOSPHOGLUCONATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW MONONUCLEAR CELL; CELL MATURATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GRANULOPOIESIS; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MASS SPECTROMETRY; MYELOBLAST; MYELOPOIESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMYELOCYTE; PROTEOMICS; THERAPY RESISTANCE; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANNEXIN A1; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM PROTEINS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84866064773     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.030     Document Type: Article

References (37)

1. Stone R.M., O'Donnell M.R., Sekeres M.A. Acute myeloid leukemia. Hematology 2004, 98-117.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
3. Bennet J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Hematol 1976, 33:451-458.
4. WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer (IARC), Lyon, France 2008, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
5. Byrd J.C., Mrózek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
6. Lockhart D.J., Winzeler E.A. Genomic, gene expression and DNA arrays. Nature 2000, 405:827-836.
7. Valk P.J., Delwel R., Lowenberg B. Gene expression profiling in acute myeloid leukemia. Curr Opin Hematol 2005, 12:76-81.
8. Bullinger L., Dohner K., Bair E., Fröhling S., Schlenk R.F., Tibshirani R., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605-1616.
9. Haferlach T., Kohlmann A., Schnittger S., Dugas M., Hiddemann W., Kern W., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005, 4:1189-1198.
10. Wilson C.S., Davidson G.S., Martin S.B., Andries E., Potter J., Harvey R., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006, 108:685-696.
11. Hanash S.M., Neel J.V., Baier L.J., Rosenblum B.B., Niezgoda W., Markel D. Genetic analysis of thirty-three platelet polypeptides detected in two-dimensional polyacrylamide gels. Am J Hum Genet 1986, 38:352-360.
12. Aivado M., Spentzos D., Germing U., Alterovitz G., Meng X.Y., Grall F., et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007, 104:1307-1312.
13. Braoudaki M., Tzortzatou-Stathopoulou F., Anagnostopoulos A.K., Papathanassiou C., Vougas K., Karamolegou K., et al. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses. Amino Acids 2010, 3:943-951.
14. Kwak J.Y., Ma T.Z., Yoo M.J., Choi B.H., Kim H.G., Kim S.R., et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004, 32:836-842.
15. Cui J.-W., Wang J., He K., Jin B.F., Wang H.X., Li W., et al. Two-dimensional electrophoresis protein profiling as an analytical tool for human acute leukemia classification. Electrophoresis 2005, 26:268-279.
16. López-Pedrera C., Villalba J.M., Siendones E., Barbarroja N., Gómez-Díaz C., Rodríguez-Ariza A., et al. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 2006, 6:S293-S299.
17. Bakhi M.Y., Trivedi A.K., Geletu M., Christopeit M., Bohlander S.K., Behre H.M., et al. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 2006, 25:7041-7058.
18. Kornblau S.M., Tibes R., Qiu Y.H., Chen W., Kantarjian H.M., Andreeff M., et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113:154-164.
19. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
20. Luczak M., Formanowicz D., Pawliczak E., Wanic-Kossowska M., Wykretowicz A., Figlerowicz M. Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Sci 2011, 9:25.
21. Giefing M., Zemke N., Brauze D., Kostrzewska-Poczekaj M., Luczak M., Szaumkessel M., et al. High resolution array-CGH and expression profiling identifies PCDH17/PCH68 and PTPRD as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 2011, 50:154-166.
22. Cho J.-W., Kim J.J., Park S.G., Lee D.H., Lee S.C., Kim H.J., et al. Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics 2004, 4:3456-3463.
23. Langebrake C., Brinkmann I., Teigler-Schleger A., Creutzig U., Griesinger F., Puhlmann U., et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 2005, 63:1-9.
24. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sulé N., Mrózek K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97:3574-3580.
25. Lim L.H., Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007, 21:986-975.
26. Falini B., Tiacci E., Liso A., Basso K., Sabattini E., Pacini R., Dalla Favera R., Pileri S., et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004, 363:1869-1870.
27. Jordan M.A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-130.
28. Shum M.S., Pasquier E., Po'uha S.T., O'Neill G.M., Chaponnier C., Gunning P.W., et al. γ-Actin regulates cell migration and modulates the ROCK signaling pathway. FASEB J 2011, 12:4423-4433.
29. Fenteany G., Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 2003, 3:593-616.
30. Giganti A., Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res 2003, 5:511-525.
31. Rao J., Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004, 4:345-354.
32. Rowley J.D. Biological implications of consistent chromosome rearrangements in leukemia and lymphoma. Cancer Res 1984, 44:3159-3168.
33. Seaton B.A., Dedman J.R. Annexins. Biometals 1998, 11:399-404.
34. Coméra C., Rothhut B., Cavadore J.C., Vilgrain I., Cochet C., Chambaz E., et al. Further characterization of four lipocortins from human peripheral blood mononuclear cells. J Cell Biochem 1989, 40:361-370.
35. Heasman S.A., Zaitseva L., Bowles K.M., Rushworth S.A., Macewan D.J. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2011, 9:658-668.
36. Gessner T., Vaughan L.A., Beehler B.C., Bartels C.J., Baker R.M. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells. Cancer Res 1990, 50:3921-3927.
37. Ruefli A.A., Bernhard D., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002, 99:292-298.